Novel disease targets and management approaches for diffuse large B-cell lymphoma

References

• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphoma (version 3). 2008.
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005;4:7–14.
   PubMedGoogle Scholar
• Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematol Am Soc Hematol Educ Program 2004;221–236.
   PubMedGoogle Scholar
• Shenkier TN, Voss N, Fairey R, et al Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197–204.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, et al Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Czuczman MS, LaCasce A, et al A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008:8511.
   Google Scholar
• Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003;17:2481–2495.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205–219.
   PubMed Web of Science ®Google Scholar
• Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol 2004;127:519–530.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Bhat S, Iqbal A, Olejniczak S, Kinght J, Czuczman MS. Targeting BH3-domain anti-apoptotic proteins with GX15-070 decreases DNA synthesis, induces cell death and sensitizes rituximab-sensitive and resistant non-Hodgkins lymphoma cell lines to the anti-tumor activity of chemotherapy agents. Blood 2006;108.
   Web of Science ®Google Scholar
• O'Brien SM, Claxton DF, Crump M, et al Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299–305.
   PubMed Web of Science ®Google Scholar
• Mason KD, Khaw SL, Rayeroux KC, et al The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23:2034–2041.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Bhagat G, et al The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906–2916.
   PubMed Web of Science ®Google Scholar
• Wierda G, Roberts P, Brown R, et al Pharmacokinetics, safety and anti-tumor activity of ABT-263 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Haematologica 2009;94[suppl.2]: 138 abs. 0350.
   Google Scholar
• Paoluzzi L, Gonen M, Gardner JR, et al Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111:5350–5358.
   PubMed Web of Science ®Google Scholar
• Kingsley E, Richards D, Garbo L, et al An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009:8582.
   Google Scholar
• Miller TP, Grogan TM, Dahlberg S, et al Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460–1466.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Said J, Johnson JL, et al Biologic prognostic markers in diffuse large B-cell lymphoma patients treated with dose adjusted EPOCH-R: a CALGB 50103 correlative science study. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112:476.
   Google Scholar
• Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) 2009;23:610–615.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984–5992.
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36–45.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Reeder CB, Polikoff J, et al International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008:8509.
   Google Scholar
• Lenz G, Wright GW, Emre NC, et al Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Lam LT, Davis RE, Pierce J, et al Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28–40.
   PubMed Web of Science ®Google Scholar
• Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87:163–208.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Hoare S, et al Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105–2112.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Higginbottom K, Juliger S, et al The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007;67:2783–2790.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, et al Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Furman RR, Chueng YK, et al CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007:8031.
   Google Scholar
• Dai B, Zhao XF, Hagner P, et al Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Res 2009;69:7835–7843.
   PubMed Web of Science ®Google Scholar
• Nandi S, Reinert LS, Hachem A, et al Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage. Oncogene 2007;26:2283–2289.
   PubMed Web of Science ®Google Scholar
• Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 2003;102:297–302.
   PubMed Web of Science ®Google Scholar
• Cho SH, Goenka S, Henttinen T, et al PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 2009;113:2416–2425.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Bossy B, Kimlinger T, et al Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002;8:1085–1091.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Inwards DJ, Rowland KM, Jr., et al Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113:508–514.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Smith SM. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials 2007;2:103–110.
   PubMedGoogle Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009;20:1293–1302.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005;7:646–657.
   PubMed Web of Science ®Google Scholar
• Gupta M, Stenson M, Lasho T, et al Interplay between histone deacetylases (HDACs) and STAT3: Mechanism of activated JAK/STAT3 oncogenic pathway in ABC (activated B-cell) type diffuse large B Cell lymphoma. Blood (ASH Annual Meeting Abstracts),2009;114: (Abstract 925).
   Google Scholar
• Lindemann RK. Stroma-initiated hedgehog signaling takes center stage in B-cell lymphoma. Cancer Res 2008;68:961–964.
   PubMed Web of Science ®Google Scholar
• Dierks C, Grbic J, Zirlik K, et al Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944–951.
   PubMed Web of Science ®Google Scholar
• Kim JE, Singh RR, Cho-Vega JH, et al Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 2009;22:1312–1320.
   PubMed Web of Science ®Google Scholar
• Yang W, Agrawal N, Patel J, et al Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom 2005;63:28–35.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Smith EA, Toner LE, et al The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006;12:2902–2911.
   PubMed Web of Science ®Google Scholar
• Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027–1035.
   PubMed Web of Science ®Google Scholar
• Toner LE, Vrhovac R, Smith EA, et al The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:924–932.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Duvic M, Kim Y, et al Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial. Ann Oncol 2008;19:iv162.
   Google Scholar